December 12, 2017 | 1 pm to 2 pm EST

Sponsored by

This webinar will define the priority checklist for executing a successful strategy and operational plan for commercializing molecular diagnostics. It will examine the process of bringing a product to market by highlighting all the key features required in today’s evolving healthcare environment. Financial resources needed to execute the project plan will be measured in the current climate. Participants will get an overview of key requirements for advancing molecular diagnostics through product development, including acquiring knowledge of strategy, regulatory, reimbursement, health economic, managing key opinion leaders and patient advocacy considerations.

The course is based on: Commercializing Novel IVDs: A Comprehensive Manual for Success, written by the presenter, Harry Glorikian. This unique manual provides an overview of the major components to IVD development, from product conception through commercialization, and important considerations about individual aspects of the process.

Speakers:

Harry Glorikian
General Partner
New Ventures Funds

Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, diagnostics, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends.

He is currently a General Partner at New Ventures Funds (NV). Before joining NV Funds, he served as an Entrepreneur In Residence to GE Ventures – New Business Creation Group. He currently serves on the board of GeneNews Ltd. He also serves on the advisory board of Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures).

Harry holds an MBA from Boston University and a bachelor's degree from San Francisco State University. Harry has addressed the NIH, Molecular Medicine Tri-Conference, World Theranostics Congress and other audiences, worldwide. He has authored numerous articles, appeared on CBS Evening News and been quoted regularly by Dow Jones, The Boston Globe, Los Angeles Times, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many others. He is the Author of two books: Commercializing Novel IVD’s; A Comprehensive Manual for Success and MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market.

Stan Skrzypczak
Vice President, Corporate Development and Reimbursement
Guardant Health, Inc.

Stan Skrzypczak is a seasoned executive with 30 years of life science/pharma experience (Searle Laboratories, Genentech, Genomic Health, Invitae, and currently working for Guardant Health). His commercialization experience is in the therapeutic classes of oncology, immunology, cardiology, genetics, pulmonary diseases, and growth disorders. His experience ranges from commercializing drugs/biologics, tumor gene expression profiling assays, and NGS-based genetic laboratory tests to NGS liquid biopsy cancer diagnostics. Stan is currently the Vice President, Corporate Development and Reimbursement at Guardant Health. Guardant Health is a global leader in the field of liquid-based NGS somatic assays. He leads international commercialization and U.S reimbursement. Previously, Mr. Skrzypczak served as VP, Business Development at Invitae, a genetic testing and information services company for two years. Prior to Invitae, he was Senior Director, Marketing for a franchise product, Oncotype DX, and later he was promoted to Sr. Director, Global Strategy at Genomic Health. Genomic Health is one of the world's leading providers of genomic-based diagnostic tests that address both the over-treatment and optimal treatment of early stage cancer, one of the greatest issues in healthcare today. He was at Genentech for 18 years prior to Genomic Health working across clinical franchise areas that included oncology and immunology from a varied sales, marketing and reimbursement role and was a sales division manager for Searle Laboratories just prior to Genentech.

He has specific experience in global business and corporate development, life cycle management, marketing, sales, reimbursement, and product development. Stan has an M.S. in Immunology and an M.B.A. in Marketing.